Low Density Lipoprotein Cholesterol and Non-high Density Lipoprotein Cholesterolin Diabetic with Hemoglobin E Disorders at Surin Hospital
Article Sidebar
Main Article Content
Abstract
Objective: To evaluate the prevalence of low density lipoprotein cholesterol (LDL) of less than 100 mg/d I and non-high density lipoprotein cholesterol (non-HDL-C) of less than 130 mg/dl in diabetic patients with hemoglobin E (HbE) disorders at Surin Hospital, located in the northeastern region of Thailand.
Material and Method: The study was conducted in 3,106 diabetic patients at Surin Hospital from June, 2009 through May, 2010. Demographic and clinical data were collected. The HbE screening test and Hb typing were performed. The prevalence of HbE disorders and dyslipidemia were analyzed.
Results: The prevalence of homozygous HbE (HbEE) and HbE traits were 7.6% and 35.6% respectively. The prevalence of low density lipoprotein cholesterol (LDL) of less than 100 mg/dl and non-high density lipoprotein cholesterol (non-HDL-C) of less than 130 mg/dl in HbEE were 37.4% and 48.9%, in the HbE trait were 28.8% and 33.9%, and in the negative screening group were 28.3% and 34.2% respectively. The means of LDL and non-HDL-C were significantly lower in the HbEE than in the other groups (p<0.001 and p<0.001 respectively). The adjusted odds ratio with a 95% confidence interval (95% Cl) of LDL less than 100 mg/dl and non-HDL-C less than 130 mg/dl in HbEE when compared with the negative screening group were 1.37 (1.01-1.85) and 1.69 (1.26-2.26) respectively. The adjusted odds ratio with 95% Cl of LDL less than 100 mg/dl and non-HDL-C less than 130 mg/dl in the HbE trait when compared with the negative screening group were 1.03 (0.87-1.22) and 0.99 (0.84-1.17) respectively.
Conclusions: LDL and non-HDL-C in diabetic patients with HbEE were significantly lower than in negative screening group, whereas there were no statistical differences of LDL and non-HDL-C between diabetic patients with the HbE trait and the negative screening group.
Article Details
References
2. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival study (4S). Diabetes Care 1997;20:614-20.
3. Collins R, Armitage J, Parish S, Sleigh P, Peto R. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
4. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease withatorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
5. Pratipanawatr T, Rawdaree P, Chetthakul T, Bunnag P, Ngarmukos C, Benjasurat-wong Y, et al. Thailand diabetes registry project: Current status of dyslipidemia in Thai diabetic patients. J Med Assoc Thai 2006; 89(Suppl 1): S60-5.
6. Old JM, Olivieri NF, Thein SL. Avoidance and population control. In: Weatherall DJ, Clegg JB, Gibsons R, Higgs DR, Old JM, Olivieri NF, editors. The thalassaemia syndromes. Oxford: Blackwell Science; 2001:597-629.
7. Weatherall DJ. Introduction to the problem of hemoglobin E-beta thalassemia. J Pediatr Hematol Oncol 2000;22:551.
8. Wasi P. Haemoglobinopathies including thalassaemia. Part 1: Tropical Asia. Clin Haematol 1981;10:707-29.
9. Srisurin W. Prevalence and effect of hemoglobin E disorders on HbAlc and lipid profile of diabetic patients at Surin Hospital. J Med Assoc Thai 2011;94(1):36-42
10. Srisurin W. 12 years of participatory action research in diabetes clinic at Surin Hospital. Med J Srisaket Surin Buriram Hosp 2010;25:117-134.
11. American Diabetes Association. Standards of medical care in diabetes 2009. Diabetes Care 2009; 32(Suppl 1):S13-61.
12. American Diabetes Association. Standards of medical care in diabetes 2010. Diabetes Care 2010; 33(Suppl 1):S11-61.
13. Prayongratana K, Polprasert C, Raun- grongmorakot K, Tatone K, Santi- watanakul S. Low cost combination of DCIP and MCV was better than that of DCIP and OF in the screening for hemoglobin E. J Med Assoc Thai 2008; 91:1499-504.
14. Vichinsky E. Hemoglobin E syndromes. Hematology 2007;1:79-83.
15. Fucharoen G, Sanchaisuriya K, Sae-ung N, Dangwibul S, Fucharoen S. A simplified screening strategy for thalassaemia and haemoglobin E in rural communities in south-east Asia. Bull World Health Organ 2004;82:364-72.
16. World Health Organization. Methods of assessing iron status. In: Iron deficiency anaemia: assessment, prevention and control. A guide for programme managers. WHO/NHD/01.3. Geneva: WHO; 2001:33-45.
17. Srisurin W. Non-pharmacological therapy for low-density lipid-cholesterol levels in type-2 diabetic patients at Surin Hospital. Intern Med J Thai 2002;18:238-44.
18. Parris E5, Lawrence DB, Mohn LA, Long BL. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care 2005; 28: 595-9.
19. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61.
20. Little RR, Rohlfing CL, Hanson S, Connolly S, Higgins T, Weykamp CW, et al. Effects of hemoglobin (Hb) E and HbD traits on measurements of glycated Hb (HbAlc) by 23 methods. Clin Chem 2008;54:1277-82.
21. Paisooksantivatana K, Kongsomgan A, Banyatsuppasin W, Khupulsup K. Influence of hemoglobin E on measurement of hemoglobin Ale by immunoassays. Diabetes Res Clin Pract 2009;83:e84-85.
22. Wasi p, Pootrakul S, Pootrakul P, Prawat-muang P, Winichagoon P, Fucharoen S. Thalassemia in Thailand. Ann N Y Acad Sci 1980;344:352-63.
23. Kuypers FA. Membrane lipid alterations in hemoglobinopathies. Hematology Am Soc Hematol Educ Program 2007;68-73.
24. Luechapudiporn R, Morales NP, Fucharoen S, Chantharaksri U. The reduction of cholesteryl linoleate in lipoproteins: an index of clinical severity in beta-thalassemia/Hb E. Clin Chem Lab Med 2006; 44:574-81.
25. Lu W, Resnick HE, Jablonski KA, Jones KL, Jain AK, Howard WJ, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes. Diabetes Care 2003;26: 16-23.
